Alferminogene tadenovec

N/A

Report date: 2023/10/26 16:04:12

Base Information

Drug NameAlferminogene tadenovec
Drug Alias Name他米诺集Generx microvascular therapy他-阿米诺近Angiogenic gene therapyFGF-4 angiogenic DNA +[14] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionFGF-4 gene transference
TargetsFibroblast growth factor 4
Therapy Area/IndicationsAngina, Stable
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCardium Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAngionetics IncHuapont Life Sciences Co Ltd
Inactive CompaniesN/A
Active IndicationsAngina, Stable
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A